Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Mek162
2. Mektovi
1. 606143-89-9
2. Mek162
3. Arry-162
4. Mektovi
5. Arry-438162
6. Mek-162
7. 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide
8. Arry 438162
9. Arry 162
10. Binimetinib (mek-162)
11. Nvp-mek162
12. Mek162 (arry-162, Arry-438162)
13. Mfcd22124525
14. Binimetinib (mek162, Arry-162, Arry-438162)
15. 181r97mr71
16. 6-(4-bromo-2-fluoroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
17. 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide
18. 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide.
19. 5-(4-bromo-2-fluoroanilino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide
20. Binimetinib [usan:inn]
21. Binimetinibum
22. Unii-181r97mr71
23. 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide
24. 5-(4-bromo-2-fluorophenylamino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo(d)imidazole-6-carboxamide
25. 5-(4-bromo-2-fluorophenylamino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide
26. Mektovi (tn)
27. Arry-162; Arry-438162; Mek 162; Arry 162; Arry 438162
28. Binimetinib; Mek162
29. Mek162(binimetinib)
30. Binimetinib [mi]
31. Binimetinib (mek162)
32. Binimetinib [inn]
33. Binimetinib [jan]
34. Binimetinib (jan/usan)
35. Binimetinib [usan]
36. Binimetinib [who-dd]
37. Mls006011180
38. Schembl570088
39. Gtpl7921
40. Chembl3187723
41. Amy9056
42. Binimetinib [orange Book]
43. Dtxsid70209422
44. Arry-162,mek-162
45. Chebi:145371
46. Bdbm520649
47. Hms3652j14
48. Hms3747g09
49. Bcp06780
50. Ex-a1024
51. Nsc764042
52. Nsc788187
53. Nsc799361
54. S7007
55. Zinc38460704
56. Akos026750517
57. Ccg-269133
58. Cs-0627
59. Db11967
60. Nsc-764042
61. Nsc-788187
62. Nsc-799361
63. Sb16501
64. Ncgc00345804-01
65. Ncgc00345804-10
66. 1073666-70-2
67. 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methylbenzimidazole-6-carboxamide
68. 6-(4-bromo-2-fluorophenylamino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-3h-benzo[d]imidazole-5-carboxamide
69. Ac-29023
70. As-16706
71. Da-35030
72. Hy-15202
73. Smr004702949
74. Sy284756
75. Cas:606143-89-9;mek162
76. Ft-0697088
77. Sw219910-1
78. D10604
79. Binimetinib;mek-162; Arry-162;arry-438162
80. J-516581
81. Q19903515
82. Us11147816, Binimetinib (arry-162, Arry-438162)
83. 1h-benzimidazole-6-carboxamide, 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-
84. 5-((4-bromo-2-fluorophenylamino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo (d) Imidazole-6-carboxamide
85. 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-1,3-benzodiazole-6-carboxamide
86. 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxami
87. 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxyethyoxy)-amide
88. 6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
89. N-(2-hydroxyethoxy)-4-fluoro-5-(2-fluoro-4-bromophenylamino)-1-methyl-1h-benzoimidazole-6-carboxamide
90. Qo7
| Molecular Weight | 441.2 g/mol |
|---|---|
| Molecular Formula | C17H15BrF2N4O3 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 6 |
| Exact Mass | 440.02956 g/mol |
| Monoisotopic Mass | 440.02956 g/mol |
| Topological Polar Surface Area | 88.4 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 521 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Treatment of colorectal carcinoma
Treatment of melanoma
Binimetinib is a MEK inhibitor. MEK is an enzyme that regulates the biosynthesis of the inflammatory cytokines TNF, IL-6 and IL-1. MEK inhibitors interfere with these biosynthetic processes. It is a chemotherapeutic agent that has anti-tumor activity,.
L01EE03
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EE - Mitogen-activated protein kinase (mek) inhibitors
L01EE03 - Binimetinib
Absorption
Following oral administration in a pharmacokinetic study, at least 50% of the binimetinib dose was absorbed with a median time to maximum concentration (Tmax) of 1.6 hours. The administration of a single dose of MEKTOVI 45 mg with a high-fat, high-calorie meal (consisting of approximately 150 calories from protein, 350 calories from carbohydrate, and 500 calories from fat) in healthy subjects had no effect on binimetinib exposure.
Route of Elimination
Following a single oral dose of 45 mg radiolabeled binimetinib in healthy subjects, 62% (32% unchanged) of the administered dose was recovered in the feces while 31% (6.5% unchanged) was recovered in the urine.
Volume of Distribution
The geometric mean (CV%) of apparent volume of distribution of binimetinib is 92 L (45%)
Clearance
20.2 L/h (24%)
The primary metabolic pathway is glucuronidation with UGT1A1 contributing up to 61% of the binimetinib metabolism. Other pathways of binimetinib metabolism include N-dealkylation, amide hydrolysis, and loss of ethane-diol from the side chain. The active metabolite M3 produced by CYP1A2 and CYP2C19 represents 8.6% of the binimetinib exposure. Following a single oral dose of 45 mg radiolabeled binimetinib, approximately 60% of the circulating radioactivity AUC in plasma was attributable to binimetinib.
The mean (CV%) terminal half-life (t1/2) of binimetinib is 3.5 hours (28.5%).
Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. The inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors. This process can result in the inhibition of growth factor-mediated cell signaling. This may lead to the inhibition of tumor cell proliferation and an inhibition in the production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are themselves threonine and tyrosine kinases that possess a dual specificity. They subsequently contribute critically to the activation of the RAS/RAF/MEK/ERK pathway and are typically upregulated in a number of different tumor cell types.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-02-15
Pay. Date : 2022-01-06
DMF Number : 36434
Submission : 2021-12-09
Status : Active
Type : II
Date of Issue : 2025-09-19
Valid Till : 2028-05-05
Written Confirmation Number : WC-0349
Address of the Firm :
NDC Package Code : 54893-0119
Start Marketing Date : 2021-12-09
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2022-05-13
Pay. Date : 2022-04-19
DMF Number : 36600
Submission : 2021-12-30
Status : Active
Type : II
Date of Issue : 2025-08-22
Valid Till : 2028-08-21
Written Confirmation Number : WC-0082
Address of the Firm :

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40805
Submission : 2024-11-27
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
NDC Package Code : 81955-0022
Start Marketing Date : 2018-06-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2022-05-13
Pay. Date : 2022-04-19
DMF Number : 36600
Submission : 2021-12-30
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2022-02-15
Pay. Date : 2022-01-06
DMF Number : 36434
Submission : 2021-12-09
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40805
Submission : 2024-11-27
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2025-08-22
Valid Till : 2028-08-21
Written Confirmation Number : WC-0082
Address of the Firm : Karakhadi, Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist -Vadodara, Gujara...

Date of Issue : 2025-09-19
Valid Till : 2028-05-05
Written Confirmation Number : WC-0349
Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 54893-0119
Start Marketing Date : 2021-12-09
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 81955-0022
Start Marketing Date : 2018-06-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

About the Company : ICROM is specialized in the manufacturing and contract manufacturing of Active Pharmaceutical Ingredients (APIs) and GMP intermediates. ICROM is the partner of choice for pharmaceu...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 49
2018 Revenue in Millions : 0
Growth (%) : New launch

Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 142
2019 Revenue in Millions : 49
Growth (%) :

Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 155
2020 Revenue in Millions : 142
Growth (%) : 9

Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 14
2020 Revenue in Millions : 0
Growth (%) : 100

Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 19
2021 Revenue in Millions : 14
Growth (%) : 34

Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 176
2021 Revenue in Millions : 155
Growth (%) : 14

Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 174
2022 Revenue in Millions : 176
Growth (%) : -1

Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 18
2022 Revenue in Millions : 19
Growth (%) : 4

Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 607
2023 Revenue in Millions : 477
Growth (%) : 27

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
27 Jul 2022
Reply
17 Aug 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
12
PharmaCompass offers a list of Binimetinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Binimetinib manufacturer or Binimetinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Binimetinib manufacturer or Binimetinib supplier.
A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, including repackagers and relabelers. The FDA regulates 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide supplier is an individual or a company that provides 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide active pharmaceutical ingredient (API) or 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide finished formulations upon request. The 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers may include 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide API manufacturers, exporters, distributors and traders.
click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide DMF (Drug Master File) is a document detailing the whole manufacturing process of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide active pharmaceutical ingredient (API) in detail. Different forms of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide DMFs exist exist since differing nations have different regulations, such as 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide DMF submitted to regulatory agencies in the US is known as a USDMF. 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide USDMF includes data on 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers with USDMF on PharmaCompass.
A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide written confirmation (6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide WC) is an official document issued by a regulatory agency to a 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide manufacturer, verifying that the manufacturing facility of a 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide APIs or 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide finished pharmaceutical products to another nation, regulatory agencies frequently require a 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide WC (written confirmation) as part of the regulatory process.
click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide suppliers with NDC on PharmaCompass.
6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide GMP manufacturer or 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide GMP API supplier for your needs.
A 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide CoA (Certificate of Analysis) is a formal document that attests to 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide's compliance with 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide specifications and serves as a tool for batch-level quality control.
6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide CoA mostly includes findings from lab analyses of a specific batch. For each 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide may be tested according to a variety of international standards, such as European Pharmacopoeia (6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide EP), 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide USP).